$IMNM
Immunome Inc.

2020 Form 10-K Financial Statement

#000155837021003493 Filed on March 25, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.780M $1.525M $1.530M
YoY Change 212.42% 75.86%
% of Gross Profit
Research & Development $7.486M $8.823M $8.823M
YoY Change -15.15% 28.24%
% of Gross Profit
Depreciation & Amortization $800.0K $320.0K $600.0K
YoY Change 33.33% 15.38%
% of Gross Profit
Operating Expenses $12.26M $10.35M $10.35M
YoY Change 18.49% 33.7%
Operating Profit -$12.26M -$10.35M
YoY Change 18.49%
Interest Expense -$5.580M -$96.00K -$100.0K
YoY Change 5480.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $5.576M $96.00K
YoY Change 5708.33%
Pretax Income -$17.84M -$10.44M -$10.44M
YoY Change 70.88% 32.99%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.80M -$10.44M -$10.40M
YoY Change 71.15% 32.48%
Net Earnings / Revenue
Basic Earnings Per Share -$5.26
Diluted Earnings Per Share -$5.26 -$1.125M -$1.125M
COMMON SHARES
Basic Shares Outstanding 3.390M
Diluted Shares Outstanding 3.390M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.77M $2.540M
YoY Change 1465.75% 58.75%
Cash & Equivalents $2.543M
Short-Term Investments
Other Short-Term Assets $3.130M $580.0K
YoY Change 439.66% 13.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $42.89M $3.122M $3.120M
YoY Change 1274.68% 47.87%
LONG-TERM ASSETS
Property, Plant & Equipment $1.530M $1.700M $1.700M
YoY Change -10.0% -18.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $138.0K $240.0K
YoY Change -58.33% -7.69%
Total Long-Term Assets $1.640M $1.938M $1.940M
YoY Change -15.46% -17.09%
TOTAL ASSETS
Total Short-Term Assets $42.89M $3.122M $3.120M
Total Long-Term Assets $1.640M $1.938M $1.940M
Total Assets $44.53M $5.060M $5.060M
YoY Change 780.04% 13.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.190M $548.0K $550.0K
YoY Change 116.36% 17.02%
Accrued Expenses $1.370M $666.0K $670.0K
YoY Change 104.48% 39.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $480.0K $450.0K
YoY Change 6.67% -26.23%
Total Short-Term Liabilities $3.040M $1.665M $1.670M
YoY Change 82.04% 7.05%
LONG-TERM LIABILITIES
Long-Term Debt $130.0K $110.0K
YoY Change 18.18% -80.36%
Other Long-Term Liabilities $10.00K $20.00K
YoY Change -50.0% 0.0%
Total Long-Term Liabilities $140.0K $130.0K
YoY Change 7.69% -77.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.040M $1.665M $1.670M
Total Long-Term Liabilities $140.0K $130.0K
Total Liabilities $3.180M $1.796M $1.800M
YoY Change 76.67% -15.89%
SHAREHOLDERS EQUITY
Retained Earnings -$36.60M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.35M -$35.63M $3.260M
YoY Change
Total Liabilities & Shareholders Equity $44.53M $5.060M $5.060M
YoY Change 780.04% 13.71%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$17.80M -$10.44M -$10.40M
YoY Change 71.15% 32.48%
Depreciation, Depletion And Amortization $800.0K $320.0K $600.0K
YoY Change 33.33% 15.38%
Cash From Operating Activities -$12.13M -$4.940M -$9.600M
YoY Change 26.4% 29.55%
INVESTING ACTIVITIES
Capital Expenditures $586.0K -$190.0K $233.0K
YoY Change 151.5% -201.3%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$586.0K -$190.0K -$233.0K
YoY Change 151.5% 1.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $44.85M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 49.94M 4.420M 10.77M
YoY Change 363.55% -2058.91%
NET CHANGE
Cash From Operating Activities -12.13M -4.940M -9.600M
Cash From Investing Activities -586.0K -190.0K -233.0K
Cash From Financing Activities 49.94M 4.420M 10.77M
Net Change In Cash 37.22M -710.0K 941.0K
YoY Change 3855.69% -111.49%
FREE CASH FLOW
Cash From Operating Activities -$12.13M -$4.940M -$9.600M
Capital Expenditures $586.0K -$190.0K $233.0K
Free Cash Flow -$12.72M -$4.750M -$9.833M
YoY Change 29.36% 36.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1099270
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10634245
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1667
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y10M17D
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-39580
CY2020 dei Entity Registrant Name
EntityRegistrantName
IMMUNOME, INC.
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
579000
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2020 dei City Area Code
CityAreaCode
610
CY2020 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2020 dei Trading Symbol
TradingSymbol
IMNM
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
0
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10659626
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39766000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2543000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3128000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42894000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3122000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1531000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1700000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
138000
CY2020Q4 us-gaap Assets
Assets
44525000
CY2019Q4 us-gaap Assets
Assets
5060000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
239000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2020Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
113000
CY2019Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
212000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1187000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
548000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
666000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3038000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1665000
CY2019Q4 imnm Equipment Loan Payable Net Of Current Portion
EquipmentLoanPayableNetOfCurrentPortion
113000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
18000
CY2020Q4 us-gaap Liabilities
Liabilities
3180000
CY2019Q4 us-gaap Liabilities
Liabilities
1796000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1099270
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95738000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
38894000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10634245
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
927000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54394000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36557000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44525000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5060000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7486000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8823000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4775000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1525000
CY2020 us-gaap Operating Expenses
OperatingExpenses
12261000
CY2019 us-gaap Operating Expenses
OperatingExpenses
10348000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-12261000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-10348000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5538000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-38000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-96000
CY2020 us-gaap Other Expenses
OtherExpenses
5576000
CY2019 us-gaap Other Expenses
OtherExpenses
96000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10444000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.26
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.55
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3389592
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1093959
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25205000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10444000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
48369000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7060000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6108000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38742000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
621000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10444000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
755000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
615000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
621000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
14000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5538000
CY2020 imnm Deferred Rent
DeferredRent
-2000
CY2019 imnm Deferred Rent
DeferredRent
3000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2411000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
504000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
75000
CY2020 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
698000
CY2019 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
190000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12134000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9600000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
586000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
233000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-586000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-233000
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
6800000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
500000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
44850000
CY2020 imnm Payments Of Stock Issuance Costs Relating To Temporary Equity
PaymentsOfStockIssuanceCostsRelatingToTemporaryEquity
5973000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11046000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4616000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
49000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
35000
CY2020 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
212000
CY2019 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
225000
CY2020 imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
239000
CY2019 imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
387000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49943000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10774000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37223000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
941000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1702000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
29000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
106000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
48369000
CY2020 imnm Stock Issuance Costs Included In Accounts Payable
StockIssuanceCostsIncludedInAccountsPayable
135000
CY2020 imnm Liability Classified Warrants Issued In Connection With Convertible Preferred Stock Fair Value
LiabilityClassifiedWarrantsIssuedInConnectionWithConvertiblePreferredStockFairValue
1522000
CY2020 imnm Conversion Of Liability Classified Warrants
ConversionOfLiabilityClassifiedWarrants
7060000
CY2019 us-gaap Notes Assumed1
NotesAssumed1
6800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17800000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10400000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54400000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36600000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair value of the Company’s common stock in connection with share-based compensation arrangements and the fair value of the warrant liability. Actual results could differ from these estimates.</p>
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p>
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2019 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
0
CY2020 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
0
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5500000
CY2019 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2020 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2508036
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5026882
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3805000
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3219000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
2274000
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1519000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1531000
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1700000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1100000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
845000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000
CY2020Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
527000
CY2019Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
240000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1372000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
666000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
366000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
134000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
500000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2020 us-gaap Payments For Rent
PaymentsForRent
400000
CY2019 us-gaap Payments For Rent
PaymentsForRent
300000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
74000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
61000
CY2020 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
621000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3600000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
194000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
201000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
120000
CY2020Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
2000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.830
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.737
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
CY2020Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
5.30
CY2019Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
0.36
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.69
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10202000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1560000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1355000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
82000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.079
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.068
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.326
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13693000
CY2019Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
3000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15538000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11874000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15435000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11711000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
103000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
163000
CY2020Q4 imnm Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
103000
CY2019Q4 imnm Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
163000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
18000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
21000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
46000
CY2020 us-gaap Interest Income Operating
InterestIncomeOperating
1000
CY2019 us-gaap Interest Income Operating
InterestIncomeOperating
10000
CY2020 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-38000
CY2019 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-96000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3700000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3400000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
47300000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
47700000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35300000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
35300000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
18300000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
18300000
CY2020 imnm Net Operating Loss Carryforwards Offest Percent Of Taxable Income Maximum Percentage
NetOperatingLossCarryforwardsOffestPercentOfTaxableIncomeMaximumPercentage
0.80
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
60000

Files In Submission

Name View Source Status
0001558370-21-003493-index-headers.html Edgar Link pending
0001558370-21-003493-index.html Edgar Link pending
0001558370-21-003493.txt Edgar Link pending
0001558370-21-003493-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20201231.xsd Edgar Link pending
tmb-20201231x10k.htm Edgar Link pending
tmb-20201231x10k001.jpg Edgar Link pending
tmb-20201231x10k002.jpg Edgar Link pending
tmb-20201231x10k003.jpg Edgar Link pending
tmb-20201231x10k004.jpg Edgar Link pending
tmb-20201231x10k005.jpg Edgar Link pending
tmb-20201231x10k006.jpg Edgar Link pending
tmb-20201231x10k007.jpg Edgar Link pending
tmb-20201231x10k008.jpg Edgar Link pending
tmb-20201231x10k009.jpg Edgar Link pending
tmb-20201231x10k010.jpg Edgar Link pending
tmb-20201231x10k011.jpg Edgar Link pending
tmb-20201231x10k_htm.xml Edgar Link completed
tmb-20201231xex10d26.htm Edgar Link pending
tmb-20201231xex10d27.htm Edgar Link pending
tmb-20201231xex10d27001.jpg Edgar Link pending
tmb-20201231xex31d1.htm Edgar Link pending
tmb-20201231xex31d2.htm Edgar Link pending
tmb-20201231xex32d1.htm Edgar Link pending
tmb-20201231xex32d2.htm Edgar Link pending
tmb-20201231xex4d5.htm Edgar Link pending
tmb-20201231_cal.xml Edgar Link unprocessable
tmb-20201231_def.xml Edgar Link unprocessable
tmb-20201231_lab.xml Edgar Link unprocessable
tmb-20201231_pre.xml Edgar Link unprocessable